South Africa Unapproved Weight-Loss Drugs Market Surges, Health Officials Warn of Risks

South Africa’s health authorities have identified a rapidly expanding informal market selling unapproved weight-loss drugs, including the experimental compound Retatrutide, raising concerns about public safety and regulatory gaps. According to the South African Health Products Regulatory Authority (SAHPRA), these products often bypass standard safety evaluations and may contain harmful ingredients.

What Is the Scale of the Shadow Market?

Investigations by local media and regulatory bodies reveal that unapproved weight-loss drugs are increasingly available through online platforms and informal networks. A 2024 report by the Council for Scientific and Industrial Research (CSIR) estimated that 15% of South Africans have used unregulated weight-loss products, with Retatrutide appearing in 30% of these cases. SAHPRA officials note that these drugs are often marketed as “natural” or “herbal” alternatives, misleading consumers about their safety.

What Are the Health Risks?

Retatrutide, a GLP-1 receptor agonist, is under review by the U.S. Food and Drug Administration (FDA) for obesity treatment but has not been approved in South Africa. Health experts warn that unapproved versions may lack quality control, leading to side effects such as gastrointestinal distress, hypoglycemia, or cardiovascular risks. Dr. Thandiwe Mbeki, a pharmacologist at the University of Cape Town, stated, “These products are often adulterated with unlisted ingredients, which can interact dangerously with existing medications.”

How Are Authorities Responding?

SAHPRA has launched a public awareness campaign to educate citizens on identifying counterfeit medications and reporting illegal sales. The agency also partnered with the South African Police Service to crack down on online distributors. “We are prioritizing enforcement actions against suppliers who endanger public health,” said SAHPRA spokesperson Lindiwe Nkosi. Meanwhile, the World Health Organization (WHO) has called for stricter international collaboration to address the global proliferation of unapproved pharmaceuticals.

What Should Consumers Do?

Health officials advise consumers to consult licensed healthcare providers before using weight-loss products and to verify drug approvals through SAHPRA’s official database. The National Department of Health also recommends reporting suspicious online sales to the Anti-Counterfeiting Unit. “Buying unapproved drugs is a gamble with your health,” said Dr. Mbeki. “Always prioritize verified treatments.”

As the market grows, regulators emphasize the need for vigilance. With 2024 data showing a 40% rise in reported adverse reactions linked to unregulated weight-loss products, the urgency for consumer education and enforcement has never been higher.